Search Results for: NANOPARTICLES A Revolution in the
Articles
NANOPARTICLES - A Revolution in the Development of Drug Delivery Vehicles June 1, 2017
Tim Leaver explains how his company has developed a proprietary technology for the rapid development of nanoparticles and seamless scale-up for clinical studies and commercial production, and how it is transforming the development and manufacturing of a range of nanoparticle formulations from a hit-and-miss affair to a standardized process, accelerating novel nanomedicines from the bench to the clinic.
LIPOSOMAL PEPTIDE THERAPEUTICS - Revolutionizing Oncology: Unleashing Innovative Strategies to Tackle Challenging, High-Value Drug Targets December 4, 2023
Natalia Zisman, Krishna Allamneni, PhD, and Stacy W. Blain, PhD, explain how targeting downstream signaling proteins offers a promising approach to effectively mitigate the emergence of drug resistance that precision oncology therapies leave behind.
New Issue of Cayman Currents: Lipid Nanoparticles November 9, 2023
In Cayman Currents Issue 36, Cayman Chemical showcases the ongoing discoveries and innovation advancing lipid nanoparticles (LNPs) to the forefront of modern medicine and highlights tools available to support LNP research.
Ardena & RiboPro Forge Strategic Alliance to Support the RNA Revolution With End-to-End Manufacturing of Advanced mRNA & LNP Solutions July 5, 2023
Leading contract development manufacturer of nanomedicines, Ardena, has joined forces with mRNA and LNP technology specialists RiboPro to form a new...Omega Therapeutics Announces Promising Preliminary Clinical Data for OTX-2002 From Ongoing MYCHELANGELO I Trial September 26, 2023
Omega Therapeutics, Inc. recently announced encouraging preliminary safety, tolerability, pharmacokinetic, and translational data from the initial two dose level cohorts (n=8) from Part 1 of its ongoing Phase 1/2 MYCHELANGELO I study evaluating….
SPECIAL FEATURE - Injection Devices: Designing in Sustainability, Usability & Digitization for Patient Compliance September 5, 2023
Contributor Cindy H. Dubin, in this exclusive annual feature, highlights how leading device and drug companies are working to address the challenges of usability, sustainability, and technology to increase patient compliance.
NeuBase Announces Positive Preclinical Data Supporting the Capabilities of Stealth Editors May 22, 2023
NeuBase Therapeutics, Inc. recently announced a broad set of preclinical safety and efficiency data for its Stealth Editors development program that...Blacktrace Launches Particle Works – The New Dedicated Particle Engineering Brand April 22, 2022
Particle Works’ game-changing particle engineering platforms are set to revolutionize the way customers discover, develop and scale-up particle production for a wide range of….
Silo Pharma Extends Exclusive Option Agreement for Homing Peptides February 3, 2022
Silo Pharma, Inc. recently announced it has extended its exclusive option agreement with the University of Maryland, Baltimore, to explore a novel invention generally known as….
London Heathrow Airport’s CEO, John Holland-Kaye, Pays a Visit to Micropore Technologies December 9, 2021
Following its award as a Global Britain Business Champion by London’s Heathrow Airport, Micropore Technologies was delighted to host a...Micropore Technologies Announced as a Winner in Heathrow Airport’s Global Britain Business Champion Competition September 20, 2021
Micropore Technologies is a global business that has spent many hundreds of hours travelling across the world from London’s Heathrow...Silo Pharma Enters Exclusive Option Agreement With the University of Maryland March 4, 2021
Silo Pharma, Inc. recently announced it has executed an exclusive option agreement with the University of Maryland, Baltimore to explore...FORMULATION FORUM - Rational Design & Development of Long-Acting Injectable Dosage Forms March 1, 2020
Due to the advantages of parenteral sustained-release drug delivery (also known as long-acting injectables, LAIs) different types of sustained-release injectable delivery systems have been….
INJECTABLE NANOMEDICINES - New Developments in Long-Acting Injectable Nanoformulations May 22, 2018
Dongwei Guo, PhD, and Jingjun Huang, PhD, focus on the overview of nanoproducts in the market and the technologies to make long-acting injectable nanoformulations.
DNA THERAPEUTICS - DNAbilize-ING Antisense March 15, 2018
Peter Nielsen, MBA, explains how his company’s candidates are differentiated from those in development at other companies by the type of modification to the antisense molecule and the method by which it is conveyed to its target cell.
SPECIAL FEATURE - Platform Technologies - Derisking & Transforming Drug Development September 29, 2017
Contributor Cindy H. Dubin, in this second annual report, speaks with several exciting and innovative companies whose platform technologies are transforming drug development.
SPECIAL FEATURE - Bioavailability & Solubility: New Approaches to Enhance Drug Performance February 27, 2017
Contributor Cindy H. Dubin highlights many of the latest techniques to enhance bioavailability and solubility, how to determine the right technique for your compound, and how some companies are realizing faster time to market as a result.
BIODEGRADABLE FIBERS - Enabling Controlled Pharmaceutical & Biologic Delivery for Next-Generation Medical Applications January 13, 2017
Kevin Nelson, PhD, discusses how wet-extruded fiber eliminates the traditional limitations of pharmaceuticals and biologics that may be incorporated into implantable medical devices with melt extrusion or electrospun fibers, microspheres, or nanoparticles.
Precision NanoSystems’ New Headquarters Designed to Enhance Product & Service Offerings to Customers Developing Novel Nanomedicines October 11, 2016
Precision NanoSystems (PNI) recently announced the opening of its new corporate headquarters in Vancouver, British Columbia. The custom-designed, 20,000-sq-ft facility...INDUSTRY PERSPECTIVES - The Future of the Pharma & Biotech Industries: Your Colleague’s Perspectives June 30, 2015
The Global Formulation Report in this issue provided some interesting data on what has been happening in a number of key sectors over the past 18 months. We thought it would be intriguing to hear what some of your colleagues believe will have a significant impact on the Pharma and Biotech industries throughout the next 5 to 10 years.
Company Profiles
Phosphorex
Phosphorex 35 Parkwood Dr, Suite 150 Hopkinton, MA 01748 T : (877) 288-8010 or (508) 435-9100 E: BD@phosphorex.com W: phosphorex.com ...
